Logo image of MGNX

MACROGENICS INC (MGNX) Stock Fundamental Analysis

USA - NASDAQ:MGNX - US5560991094 - Common Stock

1.6 USD
+0.13 (+8.84%)
Last: 11/13/2025, 5:22:24 PM
1.57 USD
-0.03 (-1.88%)
After Hours: 11/13/2025, 5:22:24 PM
Fundamental Rating

3

Overall MGNX gets a fundamental rating of 3 out of 10. We evaluated MGNX against 531 industry peers in the Biotechnology industry. MGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MGNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MGNX has reported negative net income.
MGNX had a negative operating cash flow in the past year.
In the past 5 years MGNX always reported negative net income.
In the past 5 years MGNX always reported negative operating cash flow.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

MGNX's Return On Assets of -14.83% is amongst the best of the industry. MGNX outperforms 80.98% of its industry peers.
MGNX's Return On Equity of -78.08% is in line compared to the rest of the industry. MGNX outperforms 53.86% of its industry peers.
Industry RankSector Rank
ROA -14.83%
ROE -78.08%
ROIC N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

MGNX has a Gross Margin of 86.91%. This is amongst the best in the industry. MGNX outperforms 88.89% of its industry peers.
MGNX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

6

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MGNX has more shares outstanding
MGNX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MGNX has an Altman-Z score of -6.40. This is a bad value and indicates that MGNX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MGNX (-6.40) is worse than 65.72% of its industry peers.
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.4
ROIC/WACCN/A
WACC8.72%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

MGNX has a Current Ratio of 5.25. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
MGNX's Current ratio of 5.25 is in line compared to the rest of the industry. MGNX outperforms 58.00% of its industry peers.
MGNX has a Quick Ratio of 5.02. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
MGNX's Quick ratio of 5.02 is in line compared to the rest of the industry. MGNX outperforms 57.44% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.02
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.09% over the past year.
Looking at the last year, MGNX shows a very strong growth in Revenue. The Revenue has grown by 303.44%.
The Revenue has been growing by 18.49% on average over the past years. This is quite good.
EPS 1Y (TTM)74.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.96%
Revenue 1Y (TTM)303.44%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%107.88%

3.2 Future

Based on estimates for the next years, MGNX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.06% on average per year.
Based on estimates for the next years, MGNX will show a decrease in Revenue. The Revenue will decrease by -2.48% on average per year.
EPS Next Y-88.32%
EPS Next 2Y-23.91%
EPS Next 3Y-23.75%
EPS Next 5Y17.06%
Revenue Next Year-57.15%
Revenue Next 2Y-47.8%
Revenue Next 3Y-40.82%
Revenue Next 5Y-2.48%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as MGNX's earnings are expected to decrease with -23.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.91%
EPS Next 3Y-23.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MACROGENICS INC

NASDAQ:MGNX (11/13/2025, 5:22:24 PM)

After market: 1.57 -0.03 (-1.88%)

1.6

+0.13 (+8.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11
Earnings (Next)03-18 2026-03-18/amc
Inst Owners71.61%
Inst Owner Change1.09%
Ins Owners1.08%
Ins Owner Change1.82%
Market Cap101.14M
Revenue(TTM)165.49M
Net Income(TTM)-36.40M
Analysts75.38
Price Target3.47 (116.88%)
Short Float %6.14%
Short Ratio4.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.29%
Min EPS beat(2)8.09%
Max EPS beat(2)18.49%
EPS beat(4)4
Avg EPS beat(4)96.65%
Min EPS beat(4)8.09%
Max EPS beat(4)316.2%
EPS beat(8)5
Avg EPS beat(8)39.88%
EPS beat(12)6
Avg EPS beat(12)13.04%
EPS beat(16)7
Avg EPS beat(16)8.15%
Revenue beat(2)2
Avg Revenue beat(2)146.46%
Min Revenue beat(2)109.73%
Max Revenue beat(2)183.18%
Revenue beat(4)3
Avg Revenue beat(4)73.34%
Min Revenue beat(4)-42.16%
Max Revenue beat(4)183.18%
Revenue beat(8)3
Avg Revenue beat(8)7.2%
Revenue beat(12)5
Avg Revenue beat(12)-2.38%
Revenue beat(16)6
Avg Revenue beat(16)-5.19%
PT rev (1m)0%
PT rev (3m)-19.05%
EPS NQ rev (1m)-8.3%
EPS NQ rev (3m)0.99%
EPS NY rev (1m)0%
EPS NY rev (3m)9.79%
Revenue NQ rev (1m)-7.4%
Revenue NQ rev (3m)19.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)90.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 2.17
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-1.66
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS2.62
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.83%
ROE -78.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.91%
FCFM N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.46%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.02
Altman-Z -6.4
F-Score6
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)32.65%
Cap/Depr(5y)40.48%
Cap/Sales(3y)2.62%
Cap/Sales(5y)4.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.96%
EPS Next Y-88.32%
EPS Next 2Y-23.91%
EPS Next 3Y-23.75%
EPS Next 5Y17.06%
Revenue 1Y (TTM)303.44%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%107.88%
Revenue Next Year-57.15%
Revenue Next 2Y-47.8%
Revenue Next 3Y-40.82%
Revenue Next 5Y-2.48%
EBIT growth 1Y60.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.54%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2475.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1548.19%
OCF growth 3YN/A
OCF growth 5YN/A

MACROGENICS INC / MGNX FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGNX.


What is the valuation status for MGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.


What is the profitability of MGNX stock?

MACROGENICS INC (MGNX) has a profitability rating of 2 / 10.